Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 11/20 | 0.59 |
| ▸ | TLR2 | O60603 | 1/20 | 0.59 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.59 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.46 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29683824 | 1.00 | ERN1 (0.59) | ERN1TLR2TLR1TLR6MAPT | |
| SCHEMBL8043039 | 0.85 | ERN1 (0.59) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL1527154 | 0.84 | ERN1 (0.69) | ERN1TLR2TLR1TLR6TDP1 | |
| SCHEMBL29459651 | 0.82 | CA1 (0.61) | ERN1TLR2TLR1TLR6TDP1 | |
| SCHEMBL1005010 | 0.82 | CA1 (0.61) | ERN1TLR2TLR1TLR6TDP1 | |
| SCHEMBL269268 | 0.82 | ALDH1A1 (0.56) | ERN1TLR2TLR1TLR6MAPT | |
| SCHEMBL31474876 | 0.82 | ALDH1A1 (0.56) | ERN1TLR2TLR1TLR6MAPT | |
| SCHEMBL26046380 | 0.81 | KDM4E (0.57) | MAPTTDP1ABCG2 | |
| SCHEMBL10331738 | 0.81 | ERN1 (0.50) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL28108940 | 0.81 | MAPT (0.49) | ERN1TLR2TLR1TLR6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118598840-A | Method for chemically synthesizing 7,2' -dihydroxyl-3 ',4' -dimethoxy isoflavane | 山西大学 | 2024-09-06 | — | — | CN | claimed |
| CN-114173750-A | Improving the stability of agents for treating keratin materials | 汉高股份有限及两合公司 | 2022-03-11 | — | — | CN | claimed |
| US-7462433-B2 | Undercoat layer containing charge transfer molecule, andTiO2; imaging layer; charge transfer molecule complexes with the TiO2 to form coordination bonds and the coordination bonds provide a reduction in ghosting; electrophotographic imaging members; improved image quality | XEROX CORPORATION (US) | 2008-12-09 | — | — | US | claimed |
| US-20070048639-A1 | Undercoat layer containing charge transfer molecule, andTiO2; imaging layer; charge transfer molecule complexes with the TiO2 to form coordination bonds and the coordination bonds provide a reduction in ghosting; electrophotographic imaging members; improved image quality | XEROX CORPORATION (US) | 2007-03-01 | — | — | US | claimed |
| US-4065504-A | Process for the methylation of hydroxybenzene derivatives | DOMTAR LIMITED (CA) | 1977-12-27 | — | — | US | claimed |
| US-12540144-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-02-03 | — | — | US | disclosed |
| CN-118598840-A | Method for chemically synthesizing 7,2' -dihydroxyl-3 ',4' -dimethoxy isoflavane | 山西大学 | 2024-09-06 | — | — | CN | disclosed |
| CN-118598840-A | Method for chemically synthesizing 7,2' -dihydroxyl-3 ',4' -dimethoxy isoflavane | 山西大学 | 2024-09-06 | — | — | CN | disclosed |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-11970448-B2 | Monomers capable of dimerizing in an aqueous solution, and methods of using same | CORNELL UNIVERSITY (US) | 2024-04-30 | — | — | US | disclosed |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| US-11603349-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD (AU) | 2023-03-14 | — | — | US | disclosed |
| US-5866513-A | Aryl-substituted cycloalkanes and cycloalkenes and herbicidal use thereof | ROHM AND HAAS COMPANY (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0887344-A1 | Quinolines and quinazolines useful in therapy | Pfizer Limited (GB) | 1998-12-30 | — | — | EP | disclosed |
| EP-0768298-A1 | Aryl-substituted cycloalkanes and cycloalkenes and herbicidal use thereof | ROHM AND HAAS COMPANY (US) | 1997-04-16 | — | — | EP | disclosed |
| CN-1137895-A | Prevention and curing agent for c attenuation living vaccine | EISAI CO LTD (JP) | 1996-12-18 | — | — | CN | disclosed |
| EP-0277894-B1 | PROCESS FOR THE PREPARATION OF TRIALKOXYBENZALDEHYDE | RHONE-POULENC CHIMIE (FR) | 1992-01-29 | — | — | EP | disclosed |
| US-4933498-A | HYDROLYZING BROMO-HYDROXY-METHOXY BENZALDEHYDE, DIRECTLY ETHERIFYING WITH A LOWER ALKYL HALIDE | RHONE-POULENC CHIMIE (FR) | 1990-06-12 | — | — | US | disclosed |
| EP-0277894-A2 | Process for the preparation of trialkoxybenzaldehyde | RHONE-POULENC CHIMIE (FR) | 1988-08-10 | — | — | EP | disclosed |
| US-4390664-A | A CURABLE GLYCIDYL ETHER OF A PHENOL-ALDEHYDE TYPE ADDUCT | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1983-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970448-B2 | Monomers capable of dimerizing in an aqueous solution, and methods of using same | CALCOCO2, MDN1, MBNL1 | ERN1 1720/4885TLR2 2239/4885TLR1 2040/4885 |
| US-11603349-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, TGFB2 | ERN1 1798/4885TLR2 604/4885TLR1 468/4885 |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | ERN1 3026/4885TLR2 444/4885TLR1 1431/4885 |
| US-12540144-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, CHP1, FKBP8 | ERN1 1914/4885TLR2 514/4885TLR1 1303/4885 |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, MTOR, FKBP14 | ERN1 2702/4885TLR2 500/4885TLR1 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.